{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q1 FY27)",
      "prediction": "BEAT",
      "answer": "pred ~$9.80 vs. cons ~$9.52",
      "confidence": "HIGH"
    },
    {
      "kpi": "Total revenue (Q1 FY27)",
      "prediction": "BEAT",
      "answer": "pred ~$106.5B vs. cons ~$104.3B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Oncology & Multispecialty adj. operating profit growth (Q1 FY27)",
      "prediction": "BEAT",
      "answer": "pred ~+16% YoY vs. cons ~+14%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY27 Adjusted EPS guidance (raise)",
      "prediction": "BETTER",
      "answer": "guide ~$44.10\u2013$44.90 (mid ~$44.50) vs. cons ~$44.30 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Annual dividend (10th consecutive hike, announced with Q1)",
      "prediction": "BETTER",
      "answer": "guide ~$0.94/qtr vs. prior $0.82 (~+15%, FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY27 capital return / buyback (accelerated by Med-Surg term loans)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.0B buyback + up to $2.25B term loans vs. cons ~$5.0B (FY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.0,
  "day5_path": "FADE",
  "day5_rationale": "Beat + modest guide raise is the base case, but the raise (~+$0.30 at the midpoint) will likely be smaller than the Q1 EPS beat (~+$0.25\u20130.30), leaving H2 estimates effectively flat-to-lower (implicit out-period trim). Combined with a stretched valuation and the sharp ~7% pre-print pullback from the $889 peak (a relief-bounce setup that can round-trip), the initial pop tends to give back over the week as sell-side revisions land only modestly higher.",
  "day5_confidence": "LOW"
}